Novo Nordisk and AI-driven protein design company Gensaic are to develop tissue-targeted therapies for cardiometabolic ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...

Nucresiran and Vutrisiran Advancements Demonstrate Durable Leadership in TTR Alnylam scientists will provide an update on the TRITON Phase 3 program for its next-generation transthyretin (TTR ...

The company provided 2025 guidance for TTR product sales of $1.6 billion to $1.725 billion, representing a 36% growth at the midpoint compared to 2024. This outlook assumes regulatory approval and the ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...

Q4 2024 Earnings Call Transcript February 13, 2025 Alnylam Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. is a better investment based on AAII's ...

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...